Zoetis (XSWX:ZTS) NonCurrent Deferred Revenue: CHF0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:ZTS Zoetis Inc XSWX:ZTS
56 GF Score
Price CHF61.67
GF Value CHF147.86
Valuation Significantly Undervalued
View Full Analysis

What is Zoetis NonCurrent Deferred Revenue?

Zoetis XSWX:ZTS +0.67% 56 NonCurrent Deferred Revenue is CHF0 Mil as of Jun. 2026. GuruFocus rates XSWX:ZTS with a GF Score™ of 56/100 and a GF Value™ of CHF147.86 (Significantly Undervalued).

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Zoetis's non-current deferred revenue for the quarter that ended in Jun. 2026 was CHF0 Mil.

Zoetis NonCurrent Deferred Revenue Related Terms

Zoetis NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Zoetis's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoetis NonCurrent Deferred Revenue Chart

Zoetis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zoetis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:ZTS
56GF Score
Zoetis Inc XSWX:ZTS
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of CHF0 Mil mean?
Zoetis (XSWX:ZTS) has a NonCurrent Deferred Revenue of CHF0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Zoetis and its competitors.
Is Zoetis' NonCurrent Deferred Revenue too high?
Zoetis' current NonCurrent Deferred Revenue is CHF0 Mil. Overall, Zoetis has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' NonCurrent Deferred Revenue compare to UTHR and VTRS?
Zoetis' NonCurrent Deferred Revenue of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Drug Manufacturers company?
A good NonCurrent Deferred Revenue depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Zoetis and its competitors. Zoetis's current NonCurrent Deferred Revenue is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF147.86, compared to a current price of CHF61.67 — trading 58.3% below its estimated fair value. The current NonCurrent Deferred Revenue is CHF0 Mil. Zoetis' overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current NonCurrent Deferred Revenue is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zoetis (XSWX:ZTS) Overvalued in 2026?

Based on GuruFocus' analysis, Zoetis stock appears to be undervalued. The current stock price of CHF61.67 is trading 58.3% below its estimated GF Value™ of CHF147.86. GuruFocus considers Zoetis to be Significantly Undervalued.

Key valuation signals for XSWX:ZTS:

  • NonCurrent Deferred Revenue: CHF0 Mil
  • GF Value™: CHF147.86 vs. price of CHF61.67 (58.3% below fair value)
  • GF Score™: 56/100

No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zoetis Business Description

Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
56GF Score

Get the complete analysis for XSWX:ZTS

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF61.67
Price
CHF147.86
GF Value